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Chronic pain presents a widespread and intractable medical problem. While numerous
pharmaceuticals are used to treat chronic pain, drugs that are safe for extended use
and highly effective at treating the most severe pain do not yet exist. Chronic pain
resulting from nervous system injury (neuropathic pain) is common in conditions ranging
from multiple sclerosis to HIV-1 infection to type II diabetes. Inflammation caused by
neuropathy is believed to contribute to the generation and maintenance of neuropathic
pain. Chemokines are key inflammatory mediators, several of which (MCP-1, RANTES,
MIP-1α, fractalkine, SDF-1 among others) have been linked to chronic, neuropathic
pain in both human conditions and animal models. The important roles chemokines
play in inflammation and pain make them an attractive therapeutic target. Peroxisome
proliferator-activated receptors (PPARs) are a family of nuclear receptors known for
their roles in metabolism. Recent research has revealed that PPARs also play a role
in inflammatory gene repression. PPAR agonists have wide-ranging effects including
inhibition of chemokine expression and pain behavior reduction in animal models.
Experimental evidence suggests a connection between the pain ameliorating effects of
PPAR agonists and suppression of inflammatory gene expression, including chemokines.
In early clinical research, one PPARα agonist, palmitoylethanolamide (PEA), shows promise
in relieving chronic pain. If this link can be better established, PPAR agonists may represent
a new drug therapy for neuropathic pain.
Keywords: neuropathic pain, MCP-1, RANTES, MIP-1α, fractalkine, SDF-1, peroxisome proliferator-activated
receptors
INTRODUCTION
Chronic pain presents a serious medical problem. Current pain
therapies show limited efficacy and many patients experience
pain that is refractory to the available treatments. Neuropathic
pain is frequently characterized by inflammation which can
lead to sensitization in both the central and peripheral nervous
systems. Key inflammatory mediators that are known to par-
ticipate in chronic pain, including chemokines, have emerged
as new therapeutic targets. Here, for the first time, we present
a review of the literature linking chemokines in neuropathic
pain to activation of peroxisome proliferator-activated recep-
tors (PPARs). Ligand bound PPARs are known to inhibit the
expression of inflammatory genes by a process termed tran-
srepression. Among the genes repressed by activated PPARs are
those of chemokines and their receptors. Early clinical tri-
als indicate that PPAR agonists can be effective at alleviating
neuropathic pain, even in patients who failed to respond to
other treatments. While much remains to be understood about
how PPAR agonists achieve this effect, it seems probable that
inhibiting the expression of pain-causing inflammatory media-
tors like chemokines represents at least one mechanism for pain
reduction.
NEUROPATHIC PAIN
Pain is defined as an unpleasant sensation induced by a noxious
stimulus. There are two commonly used criteria for distinguishing
acute from chronic pain. Acute pain is typically defined as pain
associated with an injury and pain that is relatively short in
duration. Chronic pain is sometimes defined as pain that persists
beyond the expected healing time of an injury. Alternatively,
researchers and clinicians may use arbitrary time points to define
chronic pain as pain that persists beyond this time frame, e.g.,
3 months. Acute pain serves an important function by warning
individuals of tissue damage. Chronic pain, when it is dissociated
from an injury, does not serve this purpose. Instead, chronic pain
results from dysregulation, also called sensitization, of the ner-
vous system. Persistent pain can produce permanent functional
changes in the pain perception pathway. Sensitization can occur
at all levels of the pain neuraxis, in both the central and peripheral
nervous systems (Costigan et al., 2009).
Chronic pain can be divided into two classes, nociceptive and
neuropathic. Nociceptive pain is caused by activation of nocicep-
tors in the skin, tissue, or viscera in response to injury. Neuro-
pathic pain results from damage to the somatosensory nervous
system. Peripheral neuropathies may involve injured sensory,
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motor, or autonomic nerves. In the central nervous system, injury,
stroke, or disease in the brain or spinal cord can also generate a
state of chronic, neuropathic pain. These causes of neuropathic
pain often evoke a strong immune response (Woolf and Mannion,
1999; von Hehn et al., 2012).
INFLAMMATION
Animal models of neuropathic pain have illuminated some of
the complex mechanisms that underlie the development and
maintenance of pain states after injury. Researchers have been
able to reproduce human-like pain responses in animals, and
study the mechanisms that generate such pain behaviors as well
as possible treatments. Neuropathic pain symptoms are often
heterogeneous in nature, and animal models have shown that
several mechanisms are likely involved. Mechanisms including
neuronal hyperexcitability (Wall and Gutnick, 1974; Empl et al.,
2001; Wu et al., 2002; Coull et al., 2005; Jung et al., 2008; Bedi
et al., 2010), changes in gene expression (Plunkett et al., 2001;
Barclay et al., 2002; Bhangoo et al., 2007; Sandhir et al., 2011),
and alterations in the neuronal environment (Frisén et al., 1993;
Sommer et al., 1993; Zelenka et al., 2005) not only contribute
to neuropathic pain, but may also facilitate and enhance one
another. Physical damage to the nervous system, as well as changes
in chemical and electrical signals in and around neurons con-
tributes to pain.
Inflammation is an adaptive response to bodily insults like
infection and tissue injury. The immune system response to nerve
injury alters the chemical environment of sensory and pain neu-
rons. Evidence points to a role for immune cells and inflammatory
mediators in generating not only inflammatory pain but chronic,
neuropathic pain as well (Moalem and Tracey, 2006; Medzhitov,
2008).
Many inflammatory mediators have been implicated in
cases of neuropathic pain, yet to what degree immune system
actions specifically cause and/or maintain neuropathic pain is
incompletely understood. Research in animal models supports the
conclusion that neuroimmune signaling contributes to sensory
dysregulation and neuropathic pain. At the most fundamental
level, injured neurons and glia release inflammatory mediators
that activate resident and recruit circulating immune cells. These
cells then release cytokines and chemokines that can alter neu-
ronal signaling (Calvo et al. (2012) have written a superior review
on this topic).
TREATMENTS
Recent epidemiological studies have placed the prevalence of
chronic, neuropathic pain at 6–8% in the general population
(Torrance et al., 2006; Bouhassira et al., 2008). However, the
occurrence of pain differs greatly between neuropathies. For
example, the prevalence of neuropathic pain in spinal cord injury
patients is between 25–60%; while 70–90% of patients suffering
from Guillain-Barré Syndrome report neuropathic pain (Moulin,
1998; Werhagen et al., 2004). Symptoms are many and vary from
patient to patient. Pain phenotypes are not always specific to
a neuropathy, and pain can result from neuropathy as well as
from medications taken to treat the condition (Nandi, 2012).
Patients may present multiple pain phenomena simultaneously,
and their pain phenotypes can change over time. These obser-
vations suggest that different mechanisms may be at play within
a particular neuropathic condition and even within a single
patient.
Several groups of drugs have been utilized in neuropathic
pain treatment; among them are analgesics like opiates, anti-
inflammatory drugs including steroids, tricyclic antidepressants,
anticonvulsants, antiepileptics, antihypertensives, local anesthet-
ics, sodium channel blockers, NMDA receptor antagonists,
SSRIs (selective serotonin-reuptake inhibitors), and cannabinoids
(Moulin, 1998; Pöllmann and Feneberg, 2008; Park and Moon,
2010; Nandi, 2012). Side effects are common, and the use of
nearly all these medications is complicated by concerns about
their safety and efficacy. Apprehensions about drug dependence,
tolerance, and other side effects arise when drugs are used chron-
ically, especially at increasing doses. In some cases, patients may
benefit from a treatment for a time, suddenly stop responding,
and require a new therapy. For the most extreme neuropathic
pain conditions, drugs may incompletely treat pain or fail to do
so altogether (Harden and Cohen, 2003). Drugs that are well
tolerated and effective at treating the most severe pain have yet
to be developed.
CHEMOKINES
Mediators, such as cytokines and chemokines, are vital messen-
gers in the inflammatory process playing roles as both proinflam-
matory and anti-inflammatory/prorepair signals that act upon
numerous target tissues. Cytokines and chemokines are capable
of directly influencing nociceptive transmission at every level of
the pain neuraxis (Myers et al., 2006).
Chemokines (the name is derived from their function as
CHEMOtactic cytoKINES) are small signaling molecules that
serve as inflammatory mediators. Chemokine ligands are grouped
into four families based on their amino acid sequence: alpha
(CXC), beta (CC), gamma (C), and delta (CX3C). These desig-
nations refer to the positions of two conserved cysteine residues
near the peptide’s n-terminus. Chemokines exert their functions
by binding to a family of seven transmembrane g-protein coupled
receptors (GPCRs), which are given names correlated to the
ligands they bind.
Chemokines were first identified for their role in inflammation
(Yoshimura et al., 1987). Chemokines are released by damaged
cells and have a vital function in facilitating the migration of
leukocytes to the lesioned area (Charo and Ransohoff, 2006;
Savarin-Vuaillat and Ransohoff, 2007). However, researchers
discovered that while diversification of chemokines and their
receptors correlates with the development of a complex immune
system, some chemokines predate the evolution of the immune
system (Huising et al., 2003; DeVries et al., 2006). Specifi-
cally, SDF-1 (stromal cell derived factor 1; CXCL12) and its
cognate receptor, CXCR4, are found in life forms without
immune systems. Further, SDF-1 and CXCR4 are constitutively
expressed when many chemokines are upregulated only during
inflammation. This discovery prompted increased research into
chemokines and their receptors. Now more than 50 chemokines
and 20 receptors have been identified, and the known roles they
play are more varied.
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Chemokine signaling is important for immune system home-
ostasis (immune surveillance and immune cell maturation) as
well as for inflammation. Chemokines also serve key functions
in hematopoiesis, angiogenesis and neurodevelopment. Indeed,
these roles are still observed in the adult, as SDF-1/CXCR4 sig-
naling plays a role in adult neurogenesis (Lu et al., 2002) as well
as generating tumor vasculature (Koshiba et al., 2000; Rempel
et al., 2000). More recent research has also demonstrated that
chemokines can be potent neuromodulators. They can regulate
neurotransmitter release, alter ion channel activity, and even
act as neurotransmitters themselves (Qin et al., 2005; White
et al., 2005a; Zhang et al., 2005; Sun et al., 2006; Jung et al.,
2008).
CHEMOKINE SIGNALING IN CHRONIC INFLAMMATION AND
NEUROPATHIC PAIN
Chemokine expression is a downstream effect of the inflam-
matory cascade. Chemokine transcription is typically stimulated
by “upstream cytokines” like interleukin-1β (IL-1β) and tumor
necrosis factor-α (TNFα). The upregulation of IL-1β and TNFα
by sensory neurons is a very early, post trauma event (Uçeyler
et al., 2007; Sacerdote et al., 2008). Chemokines are capable of
selectively recruiting monocytes, neutrophils, and lymphocytes,
by establishing a chemical concentration gradient, or “chemokine
gradient”. Cells expressing cognate chemokine receptors travel
this gradient toward the location of highest chemokine concentra-
tion. Chemokines not only act on their receptors to make imme-
diate alterations to cell signaling but also activate the expression
of further downstream inflammatory mediators.
Chemokines are expressed both as part of the normal inflam-
matory response and as part of the pathology of chronic inflam-
mation. Chemokine signaling has been implicated in conditions
ranging from autoimmune disorders to vascular and pulmonary
diseases, transplant rejection, and cancer. In neurological diseases
with an inflammatory component, such as multiple sclerosis,
Alzheimer’s disease and HIV-1 infection, research has shown that
chemokines serve many key roles, including the generation and
maintenance of disease associated neuropathic pain. Chemokine
expression is also observed in many animal models of neuropathy
induced pain.
Oh et al. (2001) made an important connection between
chemokines and pain in vivo when they demonstrated that injec-
tion of SDF-1, RANTES, and MIP-1α could produce hindpaw
tactile allodynia in rats. In neuroinflammation, chemokines are
released not only by resident and recruited immune cells but also
by damaged, inflamed nervous system cells. Further, neurons and
glial cells that produce chemokines are also targeted by those same
signals. DRG neurons in culture express chemokine receptors
including CXCR4, CCR4, CCR5, and CX3CR1, the fractalkine
receptor (Oh et al., 2001). Additionally, a subset of cultured DRG
neurons demonstrated strong excitation in response to adminis-
tration of chemokines including SDF-1, MCP-1, RANTES, and
fractalkine (Oh et al., 2001; White et al., 2005b). Chemokines
are coexpressed in neurons along with pain associated neuro-
transmitters including CGRP and substance P (Oh et al., 2001;
Li et al., 2003; Dansereau et al., 2008). Excitation by chemokines,
including CXCL1 and MCP-1, also prompt the release of CGRP,
further strengthening the connection between chemokines and
pain (Qin et al., 2005; Jung et al., 2008).
It is well known that chemokines and other proinflammatory
mediators make a cytotoxic environment that strongly affects
local cells (Frisén et al., 1993; Sommer et al., 1993). Further,
chemokine upregulation can persist for weeks after injury in
animal models (Flügel et al., 2001; Zhang and De Koninck, 2006;
Bhangoo et al., 2007). Thus, persistent chemokine upregulation
is not only consistent with a role in hypersensitizing nociceptors,
but also provides an attractive therapeutic target.
TARGETING CHEMOKINE SIGNALING TO TREAT NEUROPATHIC PAIN
Several of the pain treatments described above, such as tricyclic
antidepressants and NMDA receptor blockers, act primarily upon
neuronal targets. As neuron-glial cell interactions have been
recognized as fundamental to pain pathology, drugs that target
messengers like cytokines and chemokines which signal between
these different cells have drawn more attention. Several methods
may be useful in disabling chemokine-receptor communication
including antibodies and antagonists. Pharmaceutical companies
have developed and tested antagonists to a number of cytokine
and chemokine receptors with mixed results.
For example, CCR2 receptor antagonists (CCR2-RAs) are
capable of temporarily relieving pain in some animal models
when administered after the establishment of neuropathic pain.
CCR2-RAs can block established pain for a matter of hours after
injection in an lysophophatidylcholine (LPC) model (Bhangoo
et al., 2007), a chronic constriction injury model (Serrano et al.,
2010; Van Steenwinckel et al., 2011), a trigeminal pain model
(Zhang et al., 2012), and a chemotherapy drug induced pain
model (Pevida et al., 2013). A recent study by Padi et al. (2012)
used a CCR2/CCR5 receptor antagonist to treat pain. They pro-
pose that a broad-spectrum chemokine receptor antagonist may
be a more powerful therapy.
In spite of their promise, very little data has been published
on the use of CCR2-RAs to treat pain in human neuropathy.
Pease and Horuk (2009) describe CCR2-RAs in clinical trials
for a variety of human disease conditions, not simply pain
treatment (Pease and Horuk, 2009). Kalliomäki et al. (2013)
published an inconclusive study using a novel CCR2-RA to treat
post traumatic neuralgia, or pain following a traumatic event
such as surgery, injection, and radiation. The study recruited test
subjects with established pain and compared several pain mea-
sures taken before and after treatment. The researchers reported
no significant improvement in pain symptoms on any measure
between either drug group and placebo. However, they did show
an increase in plasma MCP-1, and decreased monocyte levels
suggesting that the antagonist had in fact acted upon its target.
In the end the authors attributed their underwhelming results
to tester variability, too many patient test centers, and a hetero-
geneous population of pain types and causes (Kalliomäki et al.,
2013).
While antagonists are one important avenue of therapy, their
limitations argue strongly for the development of drugs that
can better block chemokine/receptor communication. A method
for targeting chemokine signaling this way may be to limit the
gene expression of the chemokine and/or receptor. As long-term
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changes in gene expression underlie the persistent upregulation
of chemokines in chronic pain, changes in a gene’s transcriptional
regulation may allow alterations of that gene’s expression level.
Thus, in order to counteract the harmful chemokine upregulation
seen in chronic pain, targeting the regulatory elements of tran-
scription may be fruitful.
PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS
PPARs are a family of nuclear receptors which act as lipid acti-
vated transcription factors. This family consists of three different
isoforms: PPARα, PPARβ/δ, and PPARγ. These three receptors
have different tissue distributions and distinct biological roles.
However, each can affect both positive and negative regulation of
inflammatory and metabolic genes. PPARs are activated by both
endogenous ligands and synthetic drugs. Endogenous agonists
include unsaturated fatty acids, eicosanoids, prostaglandins, com-
ponents of low density lipoproteins, and derivatives of linoleic
acid. The most commonly used synthetic agonists for PPAR
receptors include the fibrates, which bind PPARα the thiazolidine-
diones (TZDs), or glitazones, which bind PPARγ and the glitazars,
which bind both.
Canonically, PPARs form heterodimers with retinoid X recep-
tors (RXRs) and bind to peroxisome proliferator response ele-
ments (PPREs) located in the promoter region of target genes.
When inactive, PPAR-RXR is bound to a corepressor complex.
Ligand binding to PPARs induces a conformational change and
the release of the corepressor complex for degradation. The
activated heterodimer then recruits a coactivator complex which
facilitates gene expression. In their capacity as metabolic regu-
lators, PPARs modulate several vital cellular functions includ-
ing adipocyte differentiation, fatty acid oxidation, and glucose
metabolism.
Research in the last decade has outlined another important
function of PPARs: the inhibition of inflammatory gene expres-
sion. A study published in Nature by Jiang et al. (1998) was the
first to demonstrate that both natural and synthetic PPARγ ago-
nists could block the production of proinflammatory cytokines,
TNFα, IL-6, and IL-1β, in cultured monocytes. In the course
of their study, the authors made the intriguing observation that
the nature of the inflammatory agent used to induce cytokine
expression in monocytes effected the outcome of the PPARγ ago-
nist treatment. Specifically, 15d-PGJ2 and troglitazone inhibited
TNFα expression in monocytes stimulated by okadaic acid or
phorbol ester but not lipopolysaccharide (LPS).
In the same issue of Nature, Ricote et al. (1998) presented
evidence that activated macrophages upregulate PPARγ. They
further demonstrated that ligand bound PPARγ inhibits inflam-
matory gene expression through a process termed transrepression
by targeting specific transcription factors including NF-κB, AP-1,
and STAT. Transrepression is any mechanism by which a nuclear
receptor, when bound to a ligand, can repress gene expression
by interaction with transcription factors and regulatory proteins,
not by direct interaction with specific DNA sequences. There are
several forms of transrepression, including histone modification,
block of RNA polymerase hyperphosphorylation, coactivator
complex disruption, coactivator complex competition, inhibition
of corepressor clearance, etc. (Pascual and Glass, 2006).
PPAR FUNCTIONS IN INFLAMMATION
While PPARα and β/δ have pertinent anti-inflammatory effects,
the role of PPARγ as a negative regulator of inflammatory genes,
has been more completely explored. As outlined above, inac-
tivated PPARγ-RXR binds to a corepressor complex at PPREs
preventing gene expression. However, according to Christopher
Glass and colleagues (Pascual et al., 2005), PPARγ is also capable
of transrepressing inflammatory gene expression in macrophages
by inhibiting corepressor clearance (Figure 1). Under basal condi-
tions, corepressor complexes suppress inflammatory gene expres-
sion. In an inflammatory state, signaling through receptors such
as toll-like receptors (TLRs) begins an inflammatory cascade.
First, repressor complexes are ubiquinated and degraded. Next,
inhibition of NF-κB is relieved and it translocates to the nucleus
where it binds to the promoter region of target genes, initiating
transcription.
However, ligand binding to PPARγ allows receptor SUMOy-
lation, and this event directs PPARγ to a specific nuclear core-
pressor/histone deacetylase 3 complex (NCoR-HDAC3) bound to
inflammatory gene promoter regions. SUMOylated PPARγ stabi-
lizes this complex and prevents its degradation by blocking the
recruitment of ubiquinylation/19 s proteosome machinery that
is typically responsible for corepressor complex removal prior to
gene transcription. Activated PPARγ maintains the NCoR portion
of the complex in place thus keeping the target gene inactive
(Pascual et al., 2005). This research provides one mechanistic
explanation for PPARγ’s change from gene activating to gene
repressing.
Additional work by Wen et al. (2010) in mesangial cells of the
kidney has outlined a separate mechanism by which unliganded
and ligand bound PPARγ serve different functions in NF-κB
pathway facilitated gene expression (Figure 1). They reported
that PPARγ ligands, the natural agonist, 15d-PGJ2, and syn-
thetic molecules, troglitazone and ciglitazone, were able to block
TNFα induced, NF-κB dependent expression of RANTES (CCL5)
and MCP-1 (CCL2). They specifically explored the mechanism
by which suppression of RANTES was achieved. The authors
reported that downstream signalers of TNFα binding relieve inhi-
bition of the p65 subunit of NF-κB by IκB, then phosphorylate
p65, and induce its translocation to the nucleus. Once there, p65
binds to unliganded PPARγ, a relationship that is required for p65
to bind to its target κB site at the RANTES promoter and facilitate
gene transcription. Yet, when PPARγ binds a ligand, due probably
to a conformational change, PPARγ can no longer associate with
p65. Under these conditions, p65 is not able to bind to κB sites,
thus RANTES expression is transrepressed (Wen et al., 2010).
Again, this mechanism provides another method by which PPARγ
can alter its actions from promoting gene expression to actively
repressing transcription.
These two models demonstrate that transrepression is complex
and achieved by various mechanisms that are situationally-
specific. Only a small part of this process as it is played out in dif-
ferent cell types under different conditions has been illuminated.
While PPAR agonists may hold great therapeutic potential, their
actions are many and varied. Within their capability are many
positive effects, but also undesirable side effects that have unfor-
tunately limited their use. Uncovering the actions of these drugs
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FIGURE 1 | Two models of PPARγ mediated inflammatory gene
expression. (A) Under basal conditions, inflammatory gene expression
is inhibited by a corepressor complex. An inflammatory signal, such as
lipopolysaccharide (LPS) binding to TLR4, initiates an inflammatory
cascade. Inhibition of NF-κB by IκB is lifted, and NF-κB translocates to
the nucleus. The corepressor complex is removed for degradation while
NF-κB recruits a coactivator complex, binds to the target gene’s
promoter, and initiates transcription. (B) Glass and colleagues (Pascual
et al., 2005) proposed a mechanism by which activated PPARγ
transrepresses inflammatory gene expression by inhibiting corepressor
clearance. In their model, ligand binding to PPARγ allows receptor
SUMOylation, which directs PPARγ to the NCoR-HDAC3 corepressor
complex. PPARγ stabilizes this complex and prevents corepressor
degradation, thus blocking gene transcription. (C) Wen et al. (2010)
described a very different mechanism by which liganded and unliganded
PPARγ have opposing effects on RANTES gene transcription. In their
model, downstream TNFα inflammatory signals relieve NF-κB inhibition,
phosphorylate the p65 subunit of NF-κB, and induce its nuclear
translocation. There, unliganded PPARγ is required for successful
association of p65 with the RANTES promoter. (D) However, ligand
bound PPARγ is incapable of associating with p65, probably due to a
conformational change, and RANTES expression is transrepressed.
sufficiently to separate their gene activating and gene repressing
effects, inform more directed treatments, or even permit the
development of “designer” pharmaceuticals whose side-effects are
reduced will take significant further exploration (Glass and Saijo,
2010).
PPAR AGONISTS CAN ALTER CHEMOKINE EXPRESSION
A large number of studies have investigated the effects of
PPAR agonist administration on inflammatory mediator expres-
sion in many tissues and disease models. There is signifi-
cant evidence from models of diabetes, arthritis, atherosclerosis,
Parkinson’s disease, Alzheimer’s disease and others that adminis-
tration of PPAR natural ligands and synthetic agonists has anti-
inflammatory effects. Specific reductions in proinflammatory
chemokines and cytokines has been observed in numerous cells
types: renal cells (Wang et al., 2011; Lu et al., 2013), vascular
smooth muscle cells (Marchesi et al., 2013), adipocytes (Guri
et al., 2008; Ueno et al., 2012), mesothelial cells (Sauter et al.,
2012), epithelial cells (Neri et al., 2011), splenocytes (Bassaganya-
Riera et al., 2011), monocytes/macrophages (Han et al., 2005;
Tanaka et al., 2005; Hounoki et al., 2008; Liu et al., 2012),
astrocytes (Lee et al., 2008, 2012), and microglia (Kim et al.,
2012).
MCP-1/CCL2 EXPRESSION
As discussed above, signaling between monocyte chemoattrac-
tant protein-1 (MCP-1) and its cognate receptor, CCR2, has
garnered a great deal of attention by researchers seeking to
identify those chemokines that play the most important roles
in neuroinflammation and neuropathic pain. MCP-1/CCR2 sig-
naling has demonstrated some non-redundant effects, par-
ticularly in monocyte/macrophage recruitment, which make
these two a most promising therapeutic target. For exam-
ple, Abbadie et al. (2003) showed that CCR2-/- mice show
a pain free phenotype after sciatic nerve ligation, a model
of neuropathic pain, and a marked decrease in nociceptive
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behavior after formalin injection, a model of inflammatory
pain, when compared with controls. Further, MCP-1 and CCR2
remain upregulated for a long period after injury in several
models. This evidence suggests that they serve a long-lasting
function.
Information on PPARγ agonist induced inflammatory gene
repression in nervous system cells types is limited. Real time PCR
data on whole CNS tissue homogenate has shown suppression of
MCP-1 expression by TZDs in an ischemic stroke model (Tureyen
et al., 2007), a traumatic brain injury model (Yi et al., 2008),
and a spinal cord injury model (Park et al., 2007). In the latter
case, TZDs also conferred a number of neuroprotective effects
(decreased lesion size, motor neuron loss, myelin loss, astrogliosis
and microgliosis, and increased motor function recovery) via a
PPARγ dependent mechanism.
An early study in Paul Drew’s lab (Kielian et al., 2004)
tested the effects of 15d-PGJ2 effects on many cytokines and
chemokines. In a model of brain bacterial infection, 15d-
PGJ2 reduced microglial expression of several proinflammatory
cytokines including MCP-1. The group followed up with a series
of parallel studies (Storer et al., 2005a,b; Xu et al., 2005) that
tested the efficacy of endogenous and synthetic PPAR ligands
on proinflammatory cytokine and chemokine inhibition in LPS
stimulated cultured microglia and astrocytes. Both prostaglandin
PPARγ agonists, 15d-PGJ2 and PGA2, strongly inhibited MCP-
1 production in microglia. Rosiglitazone also robustly decreased
MCP-1 expression, but ciglitazone did so only at the highest
tested doses, while pioglitazone had no effect. Astrocytes showed
greater resistance to PPARγ agonist induced MCP-1 repres-
sion. PGA2 strongly inhibited MCP-1 upregulation while 15d-
PGJ2 had a modest improving effect. However, all the TZDs
had an effect only at the very highest dose. Finally, fibrates,
synthetic PPARα agonists, also blocked MCP-1 expression in
microglia.
Like astrocytes and microglia, resident and circulating
immune cells also play a large role in neuropathic pain. PPARγ is
upregulated in macrophages during inflammation, and agonists
can reduce the inflammatory migration, proliferation, infiltra-
tion, and phagocytotic ability of these cells (Ito et al., 2003;
Tureyen et al., 2007; Hounoki et al., 2008; Liu et al., 2012). MCP-
1/CCR2 signaling in macrophages is a target for PPARγ ago-
nists. Treated monocytes/macrophages show decreased migration
toward MCP-1 (Kintscher et al., 2000; Tanaka et al., 2005) and
reduced MCP-1 expression (Rival et al., 2002).
Researchers have also reported that activated PPARβ/δ can
repress MCP-1 expression in macrophages (Lee et al., 2003; Tan
et al., 2005). Lee et al. (2003) reported a mechanism by which
ligand bound and unliganded PPARβ/δ achieves differential reg-
ulation of MCP-1 expression in macrophages, which strongly
echoes the mechanism for PPARγ regulation of RANTES expres-
sion described by Wen et al. (2010), above. Lee et al. revealed
that the presence of PPARβ/δ in macrophages was associated
with proinflammatory effects which were; however, completely
blocked by the introduction of a PPARβ/δ agonist, GW501516.
They suggested that unliganded PPARβ/δ interacts with other
transcription factors to promote expression of MCP-1 and other
proinflammatory cytokines.
CCR2 is also a target for activated PPARγ research shows that
the two promoters which control CCR2 expression in monocytes
are both subject to repression by ligand bound PPARγ (Chen
et al., 2005). PPARγ agonists decrease infiltration by CCR2+
monocytes (Guri et al., 2008) likely by blocking CCR2 gene
transcription (Tanaka et al., 2005). In one study, simvastatin, from
the statin family of drugs used commonly for atherosclerosis man-
agement, was able to activate a peroxisome-proliferator response
element in a PPARγ dependent manner to produce effects similar
to those achieved by PPARγ agonists. Simvastatin treated mono-
cytes failed to migrate toward MCP-1 probably because they had
significantly decreased levels of CCR2 mRNA and protein (Han
et al., 2005).
RANTES/CCL5 EXPRESSION
RANTES (regulated on activation, normal T cell expressed and
secreted; CCL5) is another chemokine with a demonstrated role
in pain behavior and sensitization. RANTES binds the CCR5
chemokine receptor which is known as an HIV-1 coreceptor.
RANTES serves as a chemoattractant for memory T helper
cells and leukocytes including blood monocytes and eosinophils.
CCR5 expression on primary sensory neurons (Oh et al., 2001)
has been demonstrated. RANTES delivery both in the periph-
ery (Conti et al., 1998; Oh et al., 2001) and the central ner-
vous system (Benamar et al., 2008) causes pain hypersensitivity.
Finally, RANTES-/- mice show decreased nociceptive sensitiv-
ity and reduced macrophage recruitment after peripheral nerve
injury (Liou et al., 2012). While more remains to be determined
about the specific mechanisms by which RANTES participates in
neuropathic pain, this chemokine clearly plays a role in peripheral
sensitization.
In the case of RANTES, even less information exists than
does for MCP-1 regarding the ability of PPAR agonists to alter
its expression in nervous system cells. Only one such study
has connected changes in PPAR signaling with a decrease in
RANTES expression. Xiao et al. (2010) studied the effects of
steroid receptor coactivator-3 (SRC-3) deficiency in experimen-
tal autoimmune encephalomyelitis (EAE) induced mice. SCR-
3 is a p160 family coactivator that can transactivate nuclear
receptors, including PPARs. They reported that SRC3-/- mice
showed decreased disease severity and correlated a decrease in
chemokine (RANTES, MCP-1, MIP-1α, and IP-10) expression
with an increase in PPARβ/δ expression. The authors hypothe-
sized that increased PPARβ/δ signaling altered the activation state
of resident microglia, promoting an anti-inflammatory profile, as
evidenced by an increase in IL-10 and other anti-inflammatory
mediators (Xiao et al., 2010).
PPARγ agonists reduce RANTES expression in some immune
cells as well. PPARγ activation blocks RANTES expression in
immature dendritic cells (Szanto and Nagy, 2008). Interestingly,
while prostaglandins reduce RANTES expression in LPS stimu-
lated peritoneal macrophages, TZDs were unable to replicate this
effect (Kim and Kim, 2007). The authors determined that 15d-
PGJ2 and PGA were acting via a PPARγ independent mechanism.
While 15d-PGJ2 altered RANTES expression in differentiated
macrophages, it had no effect on either mRNA or protein
levels of RANTES in peripheral blood monocytes, indicating
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that differences in cell maturity constitute another situationally-
specific outcome of drug administration.
RANTES is expressed in many other tissue types during
inflammatory diseases. Animal models of inflammation in lung
(Arnold and König, 2006), gastric (Cha et al., 2011), and renal (Li
et al., 2005; Zhang et al., 2006; Wen et al., 2010) tissues show that
PPARα and γ activation can reduce RANTES levels. As outlined
above, Wen et al. (2010) described another transrepression mech-
anism by which liganded and unliganded PPARγ have opposing
effects on RANTES expression through different interactions with
the p65 subunit of NF-κB. Lastly, in human endometrial stromal
cells, Pritts et al. (2002) demonstrated that rosiglitazone and 15d-
PGJ2 act at an upstream PPRE on the RANTES promoter to
decrease the chemokine’s transcription, showing that canonical
PPARγ behavior may also have anti-inflammatory results.
MIP-1α/CCL3
MIP-1α (macrophage inflammatory protein-1α CCL3) is strongly
upregulated throughout the pain neuraxis after nervous system
injury. Increase in MIP-1α expression has been reported locally
in Schwann cells and infiltrating macrophages after sciatic nerve
injury (Kiguchi et al., 2010b) as well as in macrophages in the
dorsal root ganglion (Kim et al., 2011). Both peripheral (Kiguchi
et al., 2010a) and central (Knerlich-Lukoschus et al., 2011b)
nervous system injuries cause upregulation of MIP-1α and
it’s receptor, CCR1, in the spinal cord. Traumatic spinal cord
injury also increases the expression of MIP-1α and MCP-1 in
the thalamus, hippocampus, and periaquaductal gray (Knerlich-
Lukoschus et al., 2011a). Chemokine levels stay elevated for weeks
after injury and MIP-1α/CCR1 expression correlates well with
nociceptive behavior (Knerlich-Lukoschus et al., 2011b).
There is minimal data in the literature examining PPAR
agonist modulation of MIP-1α expression in the nervous
system. In one example of neuropathy, bacterial brain abscess,
ciglitazone had neuroprotective and anti-inflammatory effects.
Ciglitazone treatment decreased microgliosis overall, but
increased phagocytotic activity by microglia. Additionally,
protein levels of MIP-1α as well as other proinflammatory
mediators (TNFα, IL-1β, and CXCL2) were decreased in the
abscessed tissue (Kielian et al., 2004).
PPARγ signaling is also linked to decreased proinflammatory
cytokine and chemokine expression in immune cells elsewhere
in the body. Malur et al. (2009) demonstrated the importance
of PPARγ expression in alveolar macrophages to maintain lung
homeostasis. The authors reported that deletion of PPARγ in alve-
olar macrophages promoted a Th1 type inflammatory response
including an upregulation of MIP-1α and IP-10. They proposed
the use of PPARγ agonists for inflammatory lung diseases. How-
ever, an earlier study reported that 15d-PGJ2 treatment enhanced
lung inflammation caused by LPS in a mouse model. Instead of
producing an anti-inflammatory response, 15d-PGJ2 increased
edema as well as proinflammatory chemokine (MIP-1α and MCP-
1) and cytokine (IL-1β) expression.
A related study by Gosset et al. (2001) in mature dendritic
cells showed that PPARγ activation yielded variable effects on
chemokine expression depending upon the inflammatory agent
employed. In once case, stimulation by a CD40 ligand, TZDs
decreased the induced expression of MIP-1α as well as RANTES
and IP-10. However, when LPS was used, TZDs had no effect on
MIP-1α expression. This work, like that by Gurley et al. (2008)
discussed below, demonstrates the situationally-specific nature of
cellular responses to PPAR agonists.
FRACTALKINE/CX3CL1
Fractalkine, also designated CX3CL1 for the three amino acids
that separate the characteristic N-terminal cysteines, is a unique
chemokine. It is the only chemokine that can remain adhered to
cells by means of a mucin-like stalk that tethers the chemokine
domain to the plasma membrane. Cleavage by cathepsin S releases
a soluble form of fractalkine (Clark et al., 2009). Fractalkine binds
to CX3CR1, the fractalkine receptor, and is chemoattractive for T-
cells and monocytes. Endothelial cells express the tethered form
of fractalkine during inflammation. Its unique structure allows
fractalkine to attract circulating leukocytes and assist in adhering
them to the endothelium.
In chronic pain states, studies have shown a key role for
fractalkine and the fractalkine receptor in microglial activation
(Verge et al., 2004; Lindia et al., 2005; Yang et al., 2012). The
fractalkine receptor is primarily expressed in microglia in pain
related areas of the dorsal horn (Lindia et al., 2005). Intrathecal
delivery of soluable fractalkine produces nociceptive behavior
in animal models (Milligan et al., 2004; Zhuang et al., 2007).
CX3CR1-/- mice show decreased neuropathic pain and microglial
activation (Staniland et al., 2010).
In spite of abundant information about the role of fractalkine
and its receptor in neuropathic pain, no studies have yet
demonstrated the ability of any PPAR agonist to alter their
expression in the nervous system. However, PPARγ activation
has demonstrated ability to reduce fractalkine expression by
inflamed endothelial cells as well as decreased fractalkine recep-
tor expression on monocytes/macrophages (Imaizumi et al.,
2002; Bursill et al., 2010; Wan and Evans, 2010). Barlic and
Murphy (2007) reported that this PPARγ activation regulates a
change in CCR2hi/CX3CR1low monocytes promoting a change to
CCR2low/CX3CR1hi macrophages. Finally, Wan and Evans (2010)
in their paper showing negative regulation of fractalkine receptor
expression by rosiglitazone also demonstrated that an agonist
to PPARβ/δ decreased fractalkine receptor expression albeit to a
lesser extent than rosiglitazone.
Interestingly, there is evidence that fractalkine signaling may
modulate PPARγ receptor expression. Mizutani et al. (2007)
revealed that low levels of fractalkine/fractalkine receptor sig-
naling promotes an increase in PPARγ expression, thus main-
taining a low level of anti-inflammatory activity in intestinal
macrophages. They point out that intestinal macrophages are, by
necessity, hyporeactive to inflammatory stimuli. Similar to the
relationship between PPARγ and MIP-1α in alveolar macrophages
(Malur et al., 2009), these authors hypothesize that very low levels
of fractalkine signaling help maintain intestinal homeostasis by
modulating PPARγ expression.
SDF-1/CXCL12
SDF-1 (stromal cell derived factor-1; CXCL12) is an evolu-
tionarily old chemokine that serves key functions in stem cell
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migration and organ development for example in hematopoiesis,
angiogenesis, and neurogenesis, as well as playing a part in inflam-
mation. Along with other chemokines, peripheral administration
of SDF-1 is pronociceptive (Oh et al., 2001). The SDF-1 receptor,
CXCR4, is expressed in dorsal root ganglion neurons, and its
expression is upregulated after peripheral nerve injury (Oh et al.,
2001; Bhangoo et al., 2007). SDF-1 and CXCR4 expression is also
upregulated in the spinal cord in a model of traumatic spinal
cord injury (Knerlich-Lukoschus et al., 2011b). SDF-1/CXCR4
signaling has been implicated in HIV-1 associated pain; CXCR4
is a known HIV-1 coreceptor like CCR5 (Bhangoo et al., 2009).
Finally, SDF-1/CXCR4 may also involved in mediating opioid
induced neuropathic pain (Wilson et al., 2011).
A small body of evidence indicates that activated PPARγ
signaling can block SDF-1/CXCR4 facilitated lymphocyte chemo-
taxis as well as decrease both chemokine and receptor expression.
Walcher et al. (2008) demonstrated that PPARγ activation can,
within minutes, reduce SDF-1 induced migration of CD4+ lym-
phocytes (Walcher et al., 2008). This suggests some immediate
interference with an SDF-1 receptor, rather than any change in
gene expression. However, PPARγ agonists have been shown to
reduce SDF-1 expression in adipose tissue (Foryst-Ludwig et al.,
2010) and aortic grafts (Onuta et al., 2007), both inflammatory
disease models. Natural ligands and TZDs have reduced CXCR4
expression in tumor cells in a model of metastasizing cancer
(Richard and Blay, 2008). The authors cited disruption of SDF-
1/CXCR4 signaling in the metastasis of stem-like cancer cells by
a PPARγ dependent mechanism as a possible new cancer control
treatment.
PPARγ AGONIST ACTIONS MAY BE RECEPTOR DEPENDENT
OR RECEPTOR INDEPENDENT
Although PPARγ agonists have proven able to reduce inflam-
matory gene expression, to what degree these agents require the
PPARγ receptor to mediate their effects is still unclear. The evi-
dence indicates that it is common for endogenous PPARγ ligands,
particularly 15d-PGJ2, to exert effects via PPARγ independent
mechanisms. For example, Lee et al. (2008) demonstrated that
when 15d-PGJ2 decreases MCP-1 expression in INF-γ stimulated
astrocytes it does so not by binding PPARγ but instead by modu-
lating MAPK-phosphatase 1 (Figure 2). Many other studies have
confirmed that at least some of the anti-inflammatory actions
of 15d-PGJ2 are PPARγ independent (Hounoki et al., 2008; Kim
et al., 2012; Liu et al., 2012).
However, it is not only 15d-PGJ2 that shows PPARγ indepen-
dent activity. Welch et al. (2003) published data revealing that
rosiglitazone utilizes two different mechanisms, depending upon
its concentration, to alter proinflammatory gene expression in
macrophages. Rosiglitazone inhibits production of LPS and INF-
γ target genes via a PPARγ dependent mechanism at low doses,
but at high doses it employs a PPARγ independent mechanism.
The authors noted that the inhibition dose-response curve for
rosiglitazone did not match its established binding affinity for
PPARγ. So, using PPARγ-/- macrophages, they demonstrated that
rosiglitazone still repressed proinflammatory genes and deter-
mined that rosiglitazone was binding to PPARβ/δ.
Finally, there is evidence that the effects of different PPARγ
agonists may be a function of additional, modulatory signals.
Gurley et al. (2008) demonstrated that pioglitazone and troglita-
zone could have varying effects in activated astrocytes depending
upon the nature of a coadministered TLR ligand. They reported
no change in MCP-1 expression after LPS (TLR4 ligand) and
troglitazone. The same was true of single stranded RNA (TLR7/8
ligand) with troglitazone; yet ssRNA and pioglitazone facilitated
an increase in MCP-1 expression. Most fascinating, when flagellin
(TLR5 ligand) and pioglitazone were given, MCP-1 expression
increased; however, when flagellin was accompanied by troglita-
zone, MCP-1 expression decreased.
From these data, we can gather that PPARγ agonist modes of
action are complex, as are the variety of ways in which liganded
PPARγ can facilitate either gene expression or transrepression.
Further modification of activated PPARγ actions by other ligand-
receptors and their intracellular signals, can also yield different
results. Significant work remains to be done to elucidate such
situationally-specific mechanisms in order to determine why
some treatments work and others fail.
PPAR AGONISTS MODULATE NEUROPATHIC PAIN
As noted earlier, the use of PPAR agonists as a treatment has
been explored in animal models of inflammation, brain injury,
demyelination, and pain. The results of many of these studies
are encouraging. PPAR agonists have been shown, in animal
neuropathy models, to possess neuroprotective (decreased lesion
volume), anti-inflammatory (decreased microglial activation and
inflammatory gene expression), antiapoptotic (decreased number
of apoptotic neurons), antioxidative, and neurologically improv-
ing effects (Drew et al., 2005; Zhao et al., 2005; Racke et al., 2006;
Park et al., 2007; Costa et al., 2008; Yi et al., 2008; Di Cesare
Mannelli et al., 2013). As the inflammation following neuropathy
is strongly linked to the development of neuropathic pain states,
it is reasonable to ask whether or not PPAR agonists can modulate
neuropathic pain behavior in a manner similar to their anti-
inflammatory effects.
USE IN HUMANS
Evidence from several clinical trials demonstrates that the endoge-
nous PPARα agonist, palmitoylethanolamide (PEA), is an effec-
tive treatment for various human pain conditions. PEA was
identified in 1957 as a fatty acid amide with anti-inflammatory
properties (Kuehl et al., 1957). While PEA is a known agonist
of PPARα, its anti-inflammatory effects may be mediated by
additional receptors, including the other PPAR isoforms as well
as TRPV1 and cannabinoid receptors. Further, PEA appears to
have many possible target cells. Additional research is needed to
expand our understanding of the mechanisms that underlie PEA’s
effects.
PEA is available in some European countries as a dietary
supplement for medical purposes under the names Normast® and
PeaPure® indicated for the treatment of pain and inflammation.
It has demonstrated great efficacy in treating neuropathic pain,
even in patients whose pain has proven refractory to other ther-
apies (Biasiotta et al., 2010). Clinical trials have been conducted
in patients with diabetic neuropathy (Schifilliti et al., 2014),
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FIGURE 2 | PPARγ agonists inhibit MCP-1 and CCR2 expression in
inflammatory neuropathy. (A) Damage to the central nervous system
causes activation of astrocytes and resident microglia as well as recruited
macrophages. Glial cells (Van Der Voorn et al., 1999; Abbadie et al., 2003; Yan
et al., 2007; Zhang et al., 2007, 2012; Knerlich-Lukoschus et al., 2008) and
macrophages as well as neurons (Zhang and De Koninck, 2006; Gao and Ji,
2010; Zhang et al., 2012) upregulate MCP-1 and CCR2 expression as part of
the inflammatory response to injury. (B) Activated astrocytes express MCP-1,
which can be blocked by rosiglitazone and 15d-PGJ2. Lee et al. (2008)
demonstrated that 15d-PGJ2 inhibits INF-γ induced MCP-1 expression by
potentiating the activity of MAPK phosphatase-1. MKP-1 targets JNK for
dephosphorylation. This prevents the activation of the AP-1 transcription
factor subunit, c-jun, thus inhibiting AP-1 mediated MCP-1 expression. In the
case of rosiglitazone, it is unclear what mechanism is used to block MCP-1
expression; however, Lee et al. (2008) confirmed that rosiglitazone acts via
PPARγ to inhibit INF-γ induced MCP-1. (C) Activated microglia upregulate
MCP-1 and CCR2 during inflammation. Again, both rosiglitazone and
15d-PGJ2 can block MCP-1 expression. While rosiglitazone’s mechanism of
action remains unclear, studies have verified that 15d-PGJ2 is acting in a
PPARγ independent manner (Lee et al., 2008; Kim et al., 2012). Lee et al.
(2008) reported that, as in astrocytes, 15d-PGJ2 acts upon MKP-1 to block
(Continued )
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FIGURE 2 | Continued
INF-γ induced MCP-1 expression in microglia. No studies have yet examined
the effects of natural or synthetic PPARγ agonists on CCR2 expression in
activated microglia. (D) Recruited macrophages express both MCP-1 and
CCR2. Thiazolidinediones (TZDs) decrease monocyte migration toward
MCP-1 (Kintscher et al., 2000; Tanaka et al., 2005) likely by PPARγ
dependent inhibition of CCR2 gene expression (Chen et al., 2005).
However, whether or not TZDs act in a PPARγ dependent manner to block
MCP-1 expression is unknown (Hounoki et al., 2008). In the case of
15d-PGJ2, studies again indicate a PPARγ independent mechanism of
action for decreasing LPS induced MCP-1 expression (Liu et al., 2012).
15d-PGJ2 has a demonstrated ability to decrease CCR2 mRNA, yet the
mechanistic target remains to be discovered (Tanaka et al., 2005). The
ability of PPARγ agonists to decrease MCP-1 and CCR2 expression in cell
types known to be involved in neuroinflammation and pain is encouraging.
PPARγ agonists offer tantalizing hope of blocking proinflammatory
chemokine signaling between glial cells, immune cells, and neurons which
is known to be fundamental to neuropathic pain. However, these drugs
have many and varied targets which complicates their use at present.
Further research is needed to identify the mechanisms by which both
natural and synthetic PPAR agonists reduce inflammation in the nervous
system. Such knowledge will help researchers to identify the agonists best
suited to preventing chronic inflammatory chemokine expression.
postoperative pain, sciatic pain, multiple sclerosis pain (Kopsky
and Keppel Hesselink, 2012), chemotherapy pain (Truini et al.,
2011), and post-stroke pain, among other conditions (Keppel
Hesselink (2012) published a detailed review of studies using PEA
to treat chronic pain).
Several characteristics of PEA make it a very attractive pain
therapy. The first, mentioned above, is that it has been successful
at reducing pain in patients whose conditions were either unaf-
fected or incompletely treated by other medications. Second, both
clinical trials and case studies have reported no side effects of PEA
use. The lack of side effects has encouraged physicians to include
PEA alongside more traditional pain medications such as oxy-
codone and pregabalin in a multimodal treatment plan. PEA has
shown no drug-drug interactions when given with these medica-
tions. In fact, in several studies the addition of PEA to an existing
treatment regimen has increased the therapeutic effectiveness and
in some cases permitted a dose decrease of companion drugs. PEA
has also been successful in combination with non-drug treatments
such as physical therapy and acupuncture (Desio, 2010; Keppel
Hesselink, 2012; Keppel Hesselink and Hekker, 2012; Kopsky and
Keppel Hesselink, 2012; Schifilliti et al., 2014; Skaper et al., 2014).
Most recently, Sasso et al. (2013) published a study regard-
ing a novel method for manipulating the anti-inflammatory
and antinociceptive effects of PEA-PPARα signaling in animal
models. These authors reported on a novel N-acylethanolamine
acid amidase (NAAA) inhibitor, ARN077, which indirectly
prevents the degradation of PEA. PEA is produced endoge-
nously from precursors (fatty acid ethanolamides) by N-acyl-
phosphatidylethanolamide phospholipase D as needed, and its
levels are controlled by NAAA mediated hydrolysis. Sasso et al.
reported that ARN077 attenuated neuropathic pain behavior
by inhibiting NAAA activity and preserving PEA levels. Thus,
maintaining PEA levels in injured tissues either by addition of
exogenous PEA or preservation of endogenous PEA appears to
be an effective pain treatment (Taylor, 2013). Indeed, if ARN077
were to prove an effective therapy in humans, it might serve well
given in conjunction with Normast® or PeaPure®.
A NOTE ON THIAZOLIDINEDIONES
There is very little information regarding the use PPARγ agonists
for neuropathic pain treatment in humans. In part, this is the
result of conflicting data about the safety of key agonist, rosiglita-
zone. In 2007, Nissen and Wolski, published a meta-analysis of the
cardiovascular side effects of rosiglitazone (Avandia®) treatment
for type II diabetes mellitus. They concluded that rosiglitazone
use was associated with an increased risk of myocardial infarction.
In spite of a rebuttal publication by the RECORD (Rosiglitazone
Evaluated for Cardiac Outcomes and Regulation of Glycaemia
in Diabetes) study group (Home et al., 2007), the United States
Food and Drug Administration (FDA) in 2010 imposed strong
restrictions on rosiglitazone use in patients.
On November 25, 2013, the FDA delivered a press release
announcing the removal of the majority of these restrictions on
the prescription and use of Avandia after the final results of the
RECORD clinical trial [NCT00379769] (Home et al., 2009) failed
to uphold the findings of Nissen and Wolski.1 The RECORD
study results are a welcome development for rosiglitazone and
other thiazolidinedione drugs which have shown such promise for
treating diabetes and other conditions.
IN ANIMAL MODELS
Animal research has provided evidence that both natural and
synthetic ligands to PPARα and PPARγ reduce pain. Agonists
with demonstrated pain alleviating effects include the afore-
mentioned rosiglitazone, pioglitazone, and 15d-PGJ2 as well as
PEA and fenofibrate. Other synthetic PPARα agonists, GW7647
and Wy14643, also reduce pain. While these results are very
encouraging, there remains a major challenge in assessing the
collective results of animal experiments. The wide variety of pain
models, drugs, drug doses and schedules, drug administration
routes, pain assessment methods, pain assessment timepoints,
and limited investigation into the method(s) of drug action
make the identification of unifying themes extremely difficult.
However, some general conclusions can be drawn. The evidence
indicates that PPAR agonists modulate neuropathic pain in animal
models. . .
. . .by acting at targets throughout the pain neuraxis
The most potent PPAR agonist therapy requires repeated drug
administrations beginning in the early phases of pain generation.
It is logical that treatment will be more efficacious before the long-
term changes underlying sensitization have been established. Yet,
as dicussed above, PEA appears able to reduce even persistent pain
in some clinical studies. Second, there is some confusion about
the in vivo cellular targets of PPAR agonists. In some cases, dif-
ferent groups have published contradictory reports. Nevertheless,
there is evidence that PPAR agonists can act to reduce pain at
targets in the brain (D’Agostino et al., 2009; Morgenweck et al.,
2010), in the spinal cord (Churi et al., 2008; Morgenweck et al.,
2013), in the peripheral nervous system (LoVerme et al., 2006;
Takahashi et al., 2011), and in the tissue (Hasegawa-Moriyama
et al., 2012).
1www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm376516.htm
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. . .primarily via PPAR dependent mechanisms
Wherever the location and cellular target(s) of PPAR agonists may
be, the evidence points to PPARs as the primary mediators of
pain alleviation by these agonists. In neuropathic pain models,
researchers show that rosiglitazone (Park et al., 2007; Churi et al.,
2008), pioglitazone (Park et al., 2007; Maeda et al., 2008; Jia et al.,
2013; Morgenweck et al., 2013), and 15d-PGJ2 (Churi et al., 2008)
all act via PPARγ and PEA acts via PPARα (LoVerme et al., 2006;
Di Cesare Mannelli et al., 2013). The same is true in models of
inflammatory pain (D’Agostino et al., 2009) as well as of the
neuroprotective effects (Park et al., 2007; Genovese et al., 2008)
observed with these agents.
Yet, as dicussed earlier, PPAR agonists very clearly have
receptor independent effects. Although pain studies have repeat-
edly verified the PPARγ dependent actions of rosiglitazone, it
has been shown that, at high enough concentrations, rosiglita-
zone associates with PPARβ/δ (Welch et al., 2003). In another
case, researchers used antagonists to PPARγ and PPARβ/δ to
show that PEA, although not an agonist for either recep-
tor, nevertheless appears to exert some downstream effect via
these receptors (Paterniti et al., 2013). Others have tested
the contribution of PPARγ and PPARβ/δ to the antinoci-
ceptive effects of PEA and found no association (LoVerme
et al., 2006), thus further research is needed to definitively
address these conflicting reports. Similarly, Costa et al. (2008)
published their findings that PEA utilizes not PPARα, but
instead interacts with cannabinoid receptor type 1 (CB1), the
transient receptor potential cation channel vanilloid recep-
tor 1 (TRPV1), and PPARγ to reduce pain. Again, these
results contradict the findings of other studies as mentioned
above.
. . .producing both changes in gene transcription and
non-transcriptional effects
Although the receptors involved in mediating the effects of PPAR
agonists require further investigation, one downstream target of
PPAR agonist signaling, NF-κB, has been clearly identified. Sig-
nificant evidence shows that the results of PPAR agonist admin-
istration include block of IκB degradation, decreased p65 subunit
phosphorylation, and a decrease in NF-κB translocation to the
nucleus; the end result being a reduction in inflammatory gene
expression (Dehmer et al., 2004; D’Agostino et al., 2007, 2009;
Genovese et al., 2008).
However, research indicates that PPAR agonists have effects
beyond those exerted upon transcription factors like NF-κB.
Evidence shows that PPAR agonists, particularly rosiglitazone and
PEA, can relieve pain rapidly but transiently (minutes-hours)
(LoVerme et al., 2006; Churi et al., 2008; D’Agostino et al.,
2009; Khasabova et al., 2012) as well as over the long-term
(days) (Costa et al., 2008; Maeda et al., 2008; Jain et al., 2009;
Takahashi et al., 2011; Jia et al., 2013). Thus, it seems clear
that, in addition to effects that lead to modifications in gene
transcription, these agonists must also have non-transcriptional
targets. For example, LoVerme et al. (2006) reported that PEA
administration resulted in a rapid decrease in the elecrophys-
iological response of spinal nociceptors to peripheral formalin
injection.
. . .ultimately altering the expression of inflammatory mediators
including chemokines and their receptors
While the mechanistic underpinnings PPAR agonist actions are
known to be many and varied, the impact of these agents
inhibitors of inflammation is well supported. Indeed, many
studies have shown that PPAR agonists decrease the levels of
upstream inflammatory cytokines known to induce chemokine
expression, including TNFα, IL-1β, and IL-6 (Storer et al.,
2005a,b; Park et al., 2007; Loría et al., 2008; Maeda et al.,
2008; Impellizzeri et al., 2013; Jia et al., 2013; Paterniti et al.,
2013).
In a few cases, specific decreases in chemokine expression have
been reported in studies examining the effects of PPAR agonists
on animal pain conditions. Impellizzeri et al. (2013) reported
decreases in MIP-1α and MIP-2 levels after treatment with PEA
and luteolin (an antioxidant) in a mouse model of rheuma-
toid arthritis. Park et al. (2007) demonstrated that pioglitazone
decreased MCP-1 expression in spinal cord tissue in a model
of traumatic spinal cord injury. Finally, Takahashi et al. (2011)
observed a decrease in CCR2 expression in rosiglitazone-treated
macrophages. In their study, the authors were able to achieve pain
relief by transplanting these treated macrophages directly at the
site of partial sciatic nerve ligation. It is possible that this result is
part of a greater rosiglitazone effect on macrophages, as treatment
with this drug seems to promote a polarity change from M1 (pro-
inflammatory) to M2 (anti-inflammatory) (Hasegawa-Moriyama
et al., 2012, 2013).
CONCLUSIONS
In the 15 years since the first reports that PPARγ serves functions
in inflammation as well as metabolic regulation, researchers have
opened the door on a subject of breathtaking complexity. In even
these, earliest studies, investigators had begun to identify impor-
tant questions about PPAR agonist actions that remain highly
relevant today (Jiang et al., 1998; Ricote et al., 1998; Spiegelman,
1998).
The literature on PPAR signaling provides ample evidence that
PPAR agonist administration can produce situationally-specific
effects. These effects are the result, at least in part, of the abil-
ity of PPAR agonists to harness receptors other than PPARs,
and to interact not only with transcription factors to impact
gene expression but also to act at non-transcriptional targets
to produce more rapid effects. To complicate matters further,
the nature of those “situations” which generate different effects
are not fully understood. In some cases, PPAR agonists known
to bind to the same PPAR isoform, when administered under
identical conditions can yield different results. Gurley et al. (2008)
demonstrated this by showing that pioglitazone and troglita-
zone, both synthetic PPARγ agonists, produced opposite effects
on flagellin induced MCP-1 expression. In other cases, agonists
with the ability to act at the same PPAR isoform, achieve an
identical effect by completely different mechanisms. For example,
Lee et al. (2008) reported that rosiglitazone acted via a PPARγ
dependent mechanism to decrease MCP-1 expression, while 15d-
PGJ2, which is a natural ligand for PPARγ nevertheless employed
a PPARγ independent mechanism (MAPK signaling) to achieve
the same result.
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Research in animal models shows that disrupting the signaling
of important inflammatory chemokines is sufficient to achieve
pain relief. Yet, the results of efforts to translate these findings
to effective pharmaceuticals have been disappointing. It has been
speculated that redundancy in chemokine signaling prevents a
specific chemokine receptor antagonist, for example, from prov-
ing clinically effective. The heterogeneous nature of neuropathic
pain also presents a worrying medical problem. PPAR agonists
have a demonstrated ability to alter the expression of chemokines,
their receptors, and the upstream inflammatory cytokines typ-
ically responsible for stimulating chemokine expression. While,
these broad-spectrum effects are potentially the key to the ability
of PPAR agonists to reduce pain, they have also yielded some
problematic side effects.
FUTURE DIRECTIONS
Given this prohibitive complexity, the question arises: why is
it valuable to pursue greater understanding of PPAR agonists?
There are two important reasons. The first is that these agents,
both natural and synthetic, are extremely powerful. Continued
investigation into how PPAR agonists achieve anti-inflammatory
and antinociceptive effects is vital. Unlocking these mechanisms
of action has the potential to inform new, safer, and more effective
therapies. Second, these agonists are already being used effectively
in clinical settings. Whether it be PeaPure® for pain management
or Avandia® for insulin sensitization, PPAR agonists have clear,
medical value which might yet be expanded if clinical trials using
these agonists to treat conditions from cancer to dementia prove
fruitful. PEA in particular has shown unprecedented potential
to treat neuropathic pain. The apparent absence of side effects
and drug interactions is very promising. Further, researchers
and clinicians ought not overlook a treatment that has, even
occasionally, proven effective where other therapies failed.
As stated earlier, Spiegelman (1998) identified two important
questions raised by the works of Jiang et al. and Ricote et al. which
remain relevant today. First, what underlies the situationally-
specific outcomes of PPAR agonist treatment? For example, why
do PPARγ agonists yield different results depending upon the
particulars of the inflammatory response? Second, what are the
targets acted upon by PPAR ligands when PPAR independent
effects are seen? What are the relative contributions of PPARs vs.
other targets to the various results of PPAR agonist treatment?
Concerning the particular effects of PPAR agonists on
chemokine expression, there are additional questions and direc-
tions. First, PPAR agonists have a demonstrated ability to effect
the expression of chemokines. More evidence is needed from
pain models reporting the results of PPAR agonist treatment on
chemokine expression in the nervous system in areas and cell
types where chemokine signaling is known to contribute to pain.
All PPAR isoforms are known to be expressed to some extent
in parts of the central and peripheral nervous systems, although
the literature has shown that their presence may not be required
for some agonists to effect chemokine expression (Moreno et al.,
2004; van Neerven and Mey, 2007; Maeda et al., 2008; Wang et al.,
2012).
An additional question is: to what degree do PPAR agonists
alter chemokine expression directly vs. altering the expression
of upstream, inflammatory cytokines? There is abundant data
demonstrating that PPAR agonists decrease the levels of cytokines
such as TNFα, IL-1β, and IL-6 amongst others. This effect alone
might be responsible for a concomitant decrease in chemokine
expression. Yet, there is also evidence for direct action of ligand
bound PPARs at chemokine promoters and other regulatory sites.
Activated PPARs appear able to target RANTES expression both
via “canonical” behavior and transrepression (Pritts et al., 2002;
Wen et al., 2010). There is evidence for differential regulation
of MCP-1 by activated PPARβ/δ (Lee et al., 2003). Finally, the
promoters for CCR2, the receptor for MCP-1, are targets for
activated PPARγ (Chen et al., 2005).
In conclusion, PPAR agonists are powerful agents with wide-
ranging anti-inflammatory effects. Studies in animal models show
these compounds have potent antinociceptive effects as well.
Indeed, the PPARα agonist, PEA, has made a promising start
as a treatment for human neuropathic pain conditions. Much
work remains to be done to understand the complex mecha-
nisms by which PPAR agonists achieve their anti-inflammatory
and antinociceptive effects. However, the evidence to date shows
that PPAR agonists reduce the expression of many inflammatory
mediators, including specific chemokines that are known to gen-
erate and maintain chronic pain. We believe that PPAR agonists
represent an exciting new way to manage chemokine expression
in situations of neuroinflammation and pain.
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